The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.
Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.
Add Asianet Newsable as a Preferred Source
The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.
Retail sentiment on Stocktwits around Enveric Biosciences trended in the ‘bearish’ territory at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
